BQ Prime's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BQ Prime's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
Tatva Chintan Pharma Chem Ltd. Q2 FY24 operating performance missed our estimates on slower than expected recovery in structural directing agents and pressure in other segments.
Tatva Chintan is banking on acceleration in overall activity during FY25 and has guided for ~70-100% revenue growth on the base of single digit growth in FY24.
With a lack of clarity on the timing of recovery and multiple moving parts, there could be a downside risk to our FY25/26 earnings.
Upgrade to 'Accumulate' mainly considering the recent ~20% correction in the stock price.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
